Drug Profile
Research programme: anti-dengue virus therapeutics - Astellas Pharma/Nagasaki University
Latest Information Update: 06 Apr 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Nagasaki University School of Medicine
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dengue
Most Recent Events
- 01 Apr 2016 Discontinued for Dengue in Japan (unspecified route)
- 21 Mar 2013 Early research in Dengue in Japan (unspecified route)